Track topics on Twitter Track topics that are important to you
CALGARY, ALBERTA -- (Marketwired) -- 07/24/15 -- Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink") is pleased to announce that on July 20, 2015, Hepalink acquired 13,270,000 units ("Units") of Resverlogix Corp. ("RVX") by way of a private placement (the "Private Placement") at a price of Cdn.$2.67 per Unit, for an aggregate purchase price of Cdn.$35,430,900. Each Unit consists of one common share of RVX ("Common Share") plus 0.075358 of a common share purchase warrant of RVX ("Warrant") expiring five years after the closing of the Private Placement. Each whole Warrant entitles Hepalink to purchase one Common Share at an exercise price of Cdn.$2.67. The Private Placement was part of a larger offering of Units pursuant to which RVX issued 18,870,000 Units for aggregate proceeds of Cdn$50,382,900 (the "Offering").
Hepalink holds 13,270,000 Common Shares which represents 12.63% of the issued and outstanding Common Shares of RVX. Hepalink also holds 1,000,000 Warrants. Assuming all Warrants held by Hepalink are exercised, Hepalink would hold 14,270,000 Common Shares representing 13.45% of the issued and outstanding Common Shares of RVX.
The Units were acquired for investment purposes. In the future, Hepalink or any of its joint actors may, subject to applicable law, acquire or dispose of securities of RVX depending upon a number of factors, including but not limited to, general market and economic conditions and other available investment opportunities.
For further information or to obtain a copy of the early warning report, please contact Bu Haihua at 86-755-2698 0311.Contacts: Shenzhen Hepalink Pharmaceutical Co., Ltd. Bu Haihua 86-755-2698 0311 NEXT ARTICLE
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...